Vonoprazan-amoxicillin dual regimen with as a rescue therapy for : Current perspectives and implications.

Yu 's study in the (2023) introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with () for the rescue therapy against () a pathogen responsible for peptic ulcers and gastric cancer. Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression, which is minimally affected by mealtime. Compared to proton pump inhibitors, which bind irreversibly to cysteine residues in the H/K-ATPase pump, Vonoprazan competes with the K ions, prevents the ions from binding to the pump and blocks acid secretion. Concerns with increasing antibiotic resistance, effects on the gut microbiota, patient compliance, and side effects have led to the advent of a dual regimen for . Previous studies suggested that plays a role in stabilizing the gut barrier which improves eradication rate. With an acceptable safety profile, the dual-adjunct regimen was effective regardless of prior treatment failure and antibiotic resistance profile, thereby strengthening the applicability in clinical settings. Nonetheless, comes in various formulations and dosages, warranting further exploration into the optimal dosage for supplementation in rescue therapy. Additionally, larger, randomized, double-blinded controlled trials are warranted to confirm these promising results.